Skip to main content
. 2023 May 12;14(5):321. doi: 10.1038/s41419-023-05843-8

graphic file with name 41419_2023_5843_Figa_HTML.jpg

This study comprehensively evaluates the preclinical efficacy of clinical-grade hUC-MSCs in treating age-associated sarcopenia (AAS), and demonstrates that hUC-MSCs restore skeletal muscle strength and performance in two AAS mouse models via raising the expression of extracellular matrix proteins, activating satellite cells, enhancing autophagy, and impeding cellular aging, which highlights a promising strategy for AAS and other age-associated muscle diseases.